

Feb 05, 2025

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Bandra-Kurla Complex, Bandra (E), Mumbai - 400051

Scrip Code: 530019

Symbol: JUBLPHARMA

Dear Sirs,

Sub.: Intimation of Investors/ Analysts Meeting

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be **meeting** the following institutional investors in a mix of one on one and group meeting as a part of **20th India Conference organized by Nuvama Institutional Equities on February 10, 2025 at Mumbai**. The schedule may undergo change due to exigencies on the part of Investors / Analysts / Company.

- 1. 360 One
- 2. Malabar Investments
- 3. Karma Capital India
- 4. Dymon Asia Capital
- 5. GeeCee Investments
- 6. MK Ventures
- 7. Incred AMC
- 8. Purnartha Investment Advisors
- 9. Electrum capital
- 10. Anarosa Asset Management
- 11. Sundaram Alternate Assets
- 12. TCG AIF
- 13. Sanlam Asset Management Global
- 14. Nippon Life Asset Management Limited
- 15. Tata AIA Life Insurance Company Limited
- 16. White Oak Capital
- 17. Carnelian AIF

A Jubilant Bhartia Company



Jubilant Pharmova Limited

1-A, Sector 16-A, Noida-201 301, UP, India Tel: +91 120 4361000 Fax: +91 120 4234895-96 www.jubilantpharmova.com Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223 UP, India CIN : L24116UP1978PLC004624



- 18. Capri Global
- 19. Sowilo Investment Managers LLP
- 20. Unifi Mutual Fund
- 21. Kotak Mahindra Asset Management Company Ltd
- 22. Groww MF
- 23. Edelweiss Asset Management
- 24. Canara HSBC Life Insurance
- 25. Indea Capital Pte ltd
- 26. Newport Asia
- 27. Abakkus Asset Managers LLP
- 28. Baroda BNP Paribas MF
- 29. Trust MF
- 30. Creador Advisors India LLP
- 31. Lacuna GmbH
- 32. Dhanvallabh AIF

We also enclose the presentation to be discussed during the meetings.

This is for your information and record.

Thanking you,

Yours faithfully, For Jubilant Pharmova Limited

Naresh Kapoor Company Secretary

A Jubilant Bhartia Company



Jubilant Pharmova Limited 1-A, Sector 16-A, Noida-201 301, UP, India Tel: +91 120 4361000 Fax: +91 120 4234895-96 www.jubilantpharmova.com Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223 UP, India CIN : L24116UP1978PLC004624

JUBILANT PHARMOVA Investor Presentation Feb'25





Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Jubilant Bhartia Group - Snapshot



Jubilant Bhartia Group founded by Shyam S. Bhartia and Hari S. Bhartia, leading industrialists from India





Strong presence in diverse sectors like Pharmaceuticals, Life Science Ingredients, Contract Research & Development Services and Therapeutics, Performance Polymers, Food Service (QSR), Food, Auto, Consulting in Aerospace and Oilfield Services



Global presence through investments in India, USA, Canada, Europe, Singapore, Australia, Africa, China, Sri Lanka and Bangladesh



Employs around 43,000 people across the globe with ~2,200 in North America

Company Snapshot




A global pharmaceutical company with strong team of approx. 5,500 multicultural people & Total Income at Rs. 7,124 Cr. (TTM*)



4







Specialty Pharma (Radiopharma, Allergy Immunotherapy), CDMO-SI and CRDMO contributes 90% of revenues. Majority (~90% above) of revenues are USD denominated.

Global Manufacturing & Research Footprint



World class manufacturing facilities, 2 state of the art research centers & 46 radiopharmacies

Kirkland, Montreal, Canada

CDMO – Sterile Injectables



Kirkland, Montreal, Canada Radiopharmaceuticals





Spokane, Washington, USA CDMO – Sterile Injectibles Spokane, Washington, USA Allergy Immunotherapy





INDIA

NORTH

AMERICA



Roorkee, Uttrakhand, India Generics 

Nanjangud, Karnataka, India API

G. Noida, Uttar Pradesh Drug discovery, CDMO



Chemistry Innovation Research Center Greater Noida




Bengaluru, Karnataka Drug discovery

Jubilant Pharmova – Q3'FY25



Started distributing PYLARIFY[®] from PET Radiopharmacies; Successfully completed Media Fill on Line 3; Roorkee ramping up exports to US



Q3'FY25: Revenue (+9% YoY), EBITDA (+11% YoY), Net Debt / EBITDA (Reduced from 2.5x to 1.4x in 9M'FY25)

7






Radiopharmaceutical **Positron Emission Single-photon Emission Computed Tomography Therapeutics** Tomography (SPECT Imaging) (PET Imaging) (Tx) Radiation is systemically or locally delivered Uses "low-energy" radio Uses "high energy" radio using pharmaceuticals that either bind isotopes that emit gamma Description isotopes that emit positrons, Radiopharmaceutical is a rays, detected by SPECT preferentially to targeted cells or accumulate detected by a PET scanner physiologically combination of cameras radioactive isotope and Shorter half-lives pharmaceutical drug Longer half-lives Specialized / new generation isotopes Images blood flow and Images blood flow Targeted therapies with higher efficacies **Key Facts** metabolic processes Radiopharmaceuticals are Specialized but legacy Minimal off target toxicity vs. conventional Superior image quality used to diagnose and to products, > 90% generics treatments Mostly innovative, few generics treat life threatening diseases e.g. Cancer, High no. of clinical trials in the space Cardiac disorders. Large and Stable market High growth market Accelerating M&A activity in therapeutics Market Neurological disorders Robust supply chain More expensive vis-à-vis space with multiple > USD 1 Bn. deals in trends SPECT management 2023 There are **3 type of** procedures that use MAA, DTPA, radiopharmaceuticals Key Ruby-Fill ®, Pylarify, Illuccix, • ٠ Products - HICON® Sodium Iodine I 131, Products Exametazime, Sulfur Neuraceq, FDG **SPECT Imaging** Pluvicto, Lutathera Isotopes - Rb82, F18, Cu64 Colloid. Mertiatide & **PET Imaging** Isotopes - Lu177, Ac225, Pb202 Isotopes - Tc99 Isotopes **Therapeutics** Mode










US radiopharmaceutical market is expected to reach approx. USD 20 Bn. by 2030, growing at a CAGR of 20 %+

US Radiopharmaceutical Market (USD Bn.)



Growth Drivers and Key Trends

- Growth driven by superior imaging and therapeutics profiles, new emerging isotopes with low off target toxicity and increasing use cases for un-met needs
- **PET imaging market growth is** fueled by novel products, e.g., PSMA sales has exceeded USD 1 Bn. in <2 years of launch. PET market growth is driven by
 - Strong fundamentals such as better imaging, significantly lower false negatives and faster examination time
 - Applications extending beyond oncology, such as Cardiology scans, Alzheimer's
- Advanced Radiopharmaceutical Therapy market is witnessing launch of differentiated, high value and high efficacy products e.g. Pluvicto used for Prostate Cancer exceeding USD 1 Bn. sales.
 - Favorable pharmacological profile with lower toxicity and higher efficacy, especially in areas with un-met needs
 - New / emerging isotope profiles with targeted effects and lower off target impacts, such as Lu177 and Ac225
 - Application in therapeutic areas beyond oncology such as Neurological conditions, e.g. Alzheimer's

Consolidated market with high entry barriers



Stringent manufacturing & regulatory environment

Adherence with extensive license framework. Stringent manufacturing set up required to handle isotopes

Managing time sensitive logistics

Radioactive isotope decays exponentially. The half life could be few hours to few days. Goal is to deliver high activity doses

Innovative new product development

High capex requirement, long developmental cycle and complex isotope handling requirements for novel product development.

Forward integration with radiopharmacies

Forward integration with radiopharmacies helps to gain market share



We are one of largest manufacturer in the addressable market in the US with a wide radiopharmaceutical portfolio

Organ	Туре	Product	Key Indication				
Lung	Dx SPECT	Tc99m-DTPA	Pulmonary Embolism				
Lung	Dx SPECT	Tc99m-MAA	Pulmonary Perfusion				
Thyroid	Dx SPECT	I-131	Localizing metastases associated with thyroid malignancies				
• • •	Тx	I-131 HICON®	Hyperthyroidism, Selected cases of Carcinoma of Thyroid				
	Dx PET	Ruby - Fill ®	Coronary Artery disease				
Cardiac	Dx SPECT	Tc99m-Gluceptate	Cardiac blood pool Imaging				
	Dx SPECT	Tc99m-Sestamibi	Coronary Artery disease				
Breast	Dx SPECT	Sulfur Colloid	Localization of metastatic lymph nodes, imaging of liver, spleen				
Gastrointestinal	Dx SPECT	Tc99m-Exametazime	Intraabdominal Infection				
Renal	Dx SPECT	Tc99m-Mertiatide	Renal failure, Urinary tract obstruction				
Muscoskeletal	Dx SPECT	Tc99m-MDP	Delineate areas of altered osteogenesis				
Current Addressable Market ~ USD 400 Mn							

Key Differentiators

- Diversified product portfolio spread across SPECT & PET diagnostics and growing therapeutics
- **High profitability** owing to efficient cost structure, in-house APIs and robust supply chain management
- Partner of choice for leading customers owing to innovative products with superior profile vs. competitors and best in class customer service, e.g. Proprietary Ruby-Fill ® technology for Cardiac Imaging
- On-shore manufacturing facility in Montreal with high quality track record and ability to manage complex processes
- Strong R&D capabilities, continuously feeding the product pipeline to enable frequent market launches

Dx : Diagnostic, Tx : Therapeutic

Market leadership in select products - MAA, DTPA and I-131

Draximage ® MAA



Draximage ® DTPA



MAA is used in the perfusion phase of a ventilation/perfusion (V/Q) scan to diagnose pulmonary embolism. JDI is market leader in the US market

DTPA is used to assess pulmonary ventilation function in association with MAA to perform a Ventilation/perfusion (V/Q) scan. JDI is the sole supplier in the US market

HICON® is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and selected cases of carcinoma



of the thyroid. JDI has no direct competition in the US market




HICON® Sodium Iodine I 131 Solution USP



Innovation Leadership in Ruby - Fill [®], Gaining market share consistently

Growing Cardiac PET Market in the US



Source : Company Estimates

Growth Drivers and Key Trends

- Superior product profile vs. SPECT scans
- Improved reimbursement landscape and diagnostic infrastructure
- Lower half lives vs. SPECT products leading to lower hospital burden

• The RUBY-FILL® Rubidium 82 Gener

- The RUBY-FILL® Rubidium 82 Generator contains accelerator produced Strontium-82, which decays to Rubidium-82 (Rb-82). It is used for Cardiac PET scan, a non-invasive imaging procedure of the myocardium, to evaluate regional myocardial perfusion in adults with suspected or existing coronary artery disease.
- Ruby-fill is installed in top 80% US Cardiac networks and is positioned to further increase market share
- Lower cost vs. competition driven by higher shelf life of generators, hence driving more scans per generator
- Better Image quality due to patented feature of saline push dosing, significantly increasing Rb-82 activity delivered to the heart
- Consistent image quality due to proprietary constant activity mode, plus patient weight based dosing

Gaining market share in the US cardiac PET market; Installations on track in the US in Q3'FY25

Ruby-Fill[®] and Robust product pipeline to fuel future business growth





Ruby-Fill[®] Growth potential

- Gain market share in the growing US cardiac PET market
- Scale ex-US markets such as Europe, Canada, etc.



PET & SPECT Product Pipeline

- Target to launch new products in PET Imaging with an addressable market at ~ USD 500 Mn.
- Pipeline in SPECT Imaging with an addressable market at ~ USD 50 Mn.



Development of therapeutic product - MIBG

 Completed patient dosing for Phase II clinical trials for MIBG. Expect launch for relapse / refractory Neuroblastoma (~ 400 patients per annum) in CY 2026.

Driving revenue growth



Particulars (Rs. Cr.)	Q3'FY24	Q2'FY25	Q3'FY25	Y-o-Y	9M'FY24	9M'FY25	Y-o-Y
Revenue	241	251	265	10%	696	778	12%
EBITDA	126	120	125	(1%)	352	370	5%
EBITDA Margin (%)	52%	48%	47%	(550) bps	51%	48%	(300) bps

- Q3'FY25 EBITDA flattish YoY due to change in product mix, however 9M'FY25 EBITDA increased by 5% on YoY basis



US Radiopharmacy market is expected to grow on the back of novel PET & Therapeutic products

SPECT Radiopharmacy



PET Radiopharmacy





Growth Drivers and Key Trends

- Radiopharmacy dispenses and distributes radiopharmaceutical products
- Consolidated market in US with top 3 radiopharmacy networks dispensing and distributing 70%+ products
- Increasing demand of novel PET diagnostics product, e.g., Cyclotron based pharmacies for F-18 PSMA, Alzheimer's products. Additionally, SPECT pharmacies can handle generator based PET products, e.g., Ga-68 PSMA
- Therapeutics dispensing share of pharmacy networks expected to grow, driven by Stringent USP 825 regulations. Most clinics and hospitals don't want to invest in the clean room infrastructure for dispensing. Additionally, big pharma companies have limited capabilities in the distribution and handling wastes of radioactive materials
- Emerging radioisotopes landscape such as Rb-Sr, Ga-68, Cu-64, Lu-177, Ac-225 are leading to development of new PET Imaging and Theranostic products which will further fuel radiopharmacy share of dispensing and distributing these products. 16

1. USP develops uniform minimum standards for the preparation, compounding, dispensing, and repackaging of radiopharmaceuticals





Consolidated Market

	# of radio pharmacies in the US	SPECT pharmacies	PET pharmacies	# of hospitals served in the US
CardinalHealth [®]	160+	✓	✓	~ 4,100
JUBILANT RADIOPHARMA	46	✓	✓	~ 1,800
SIEMENS Healthineers PETNET Solutions	41		✓	~ 700
🔯 RLS 🧧	31	✓		~ 900
PharmaLogic Take The Lead	42	✓	✓	~ 200
	14		✓	~ 200

Barriers to Entry



Stringent Regulations

Each treatment site is required to obtain a license from Nuclear Regulatory Commission and comply with additional state, local, and hospital regulations for transportation and usage



Intricate Supply Chain

A robust supply chain is required given short product halflives and strong customer preference for just-in-time ordering, compared to large bulk orders

Complex Care Coordination

Requires awareness, education, and collaboration across multiple hospital departments

Skilled Manpower Requirement




3

Authorized nuclear pharmacists require at least 4,000 hours of training or experience in nuclear pharmacy practice along with rigorous examinations



2nd largest radiopharmacy network in the US





Investing in PET radiopharmacy network throughout the US to drive growth & profitability

PET Radiopharmacy



- Plans to invest USD 50 Mn. to expand PET radiopharmacy network by adding Six (6) sites in strategic locations throughout US
- Investment shall position the company in the growing PET Imaging segment and shall also enable the company to secure long term contracts with leading PET radiopharmaceutical manufacturers
- New PET radiopharmacies to be fully operational by FY28.
 Funding through internal accruals and long term credit
- PET radiopharmacies are expected to deliver 20% + EBITDA margins once fully operational & reaches optimum utilisation

Strengthening position by expanding PET radiopharmacy network to Nine (9) sites through out the US



Expand Radiopharmacy network, Ride on volume & new product led industry growth



Radiopharmacy Network Expansion

- Expand PET radiopharmacy network by adding six (6) PET radiopharmacies in strategic locations throughout United States.
- Evaluate opportunity to expand SPECT radiopharmacy network.



New Product led volume growth

- Increase volume for new products. Started commercial districbution of PYLARIFY® from 2 PET pharmacies
- Increase market share across Group purchasing organizations, Integrated delivery networks and independents hospitals



Enhance Operational Efficiencies

- Further strengthen performance on key pharmacy operational metrics
- Continue to improve sourcing efficiency

JUBILANT PHARMOVA

Radiopharmacy


Volume to drive revenue growth & operational efficiency to drive margin expansion

Particulars (Rs. Cr.)	Q3'FY24	Q2'FY25	Q3'FY25	Y-o-Y	9M'FY24	9M'FY25	Ү-о-Ү
Revenue	511	568	576	13%	1,488	1,715	15%
EBITDA	10	6	5	(49%)	18	24	35%
EBITDA Margin (%)	2%	1%	1%	(110) bps	1%	1%	20 bps

- Q3'FY25 revenue grew 13% YoY on the back of increase in volume from new products, however revenues growth got impacted by Industry wide Technetium shortage in Q3'FY25
- Q3'FY25 EBITDA lower YoY due to Industry wide Technetium shortage during the period, however 9M'FY25 EBITDA increased 35% YoY

Global market poised to reach USD 3 Bn. by 2028, growing at a CAGR of ~ 7%

Most Common Allergies in US (2023)



Allergy Burden in the US*


> 50 Mn. Americans suffer from some type of an allergy annually

> 20 Mn.	
Americans LIVES are impacted by House Dust Mites	respor patien it affe



>50 Deaths in US in a

year due to Anaphylaxis Global Allergy Immunotherapy Market (USD Bn.)



- Allergy immunotherapy (AIT) refers to the treatment for allergic reactions against a variety of allergens including Pollen, Mold, PET dander, Food & Insect (treated by venom immunotherapy) etc. In this treatment, repeated shots of allergic antigens are provided to develop immunity and eventually cure allergy over a period of time.
- There are two kinds of delivery mechanisms Sub Lingual and Sub Cutaneous

Growth Drivers

- Increasing allergy cases
- Awareness of allergy treatment
- Advancement in treatment options





Jubilant is #2 player in the US Sub-Cutaneous Allergy Immunotherapy market with strong entry barriers

Strong Entry Barriers

- Highly concentrated US market with well established players
- Raw material comprising natural extracts / organisms involve a complex supply chain from sourcing to processing.
- Grandfathered approvals with any new product needing a Biologic License Approval which is more complex than small molecule drug approval.
- In order to succeed, New Entrant has to offer a complete portfolio of products, which shall entail significant investment, development and approval lead times.

Key Differentiators

- # 2 player in the US SCIT allergy market & Sole Supplier of Venom immunotherapy in the US since 2018.
- Product portfolio includes 6 different Insect Venom products, 200+ allergenic extracts and skin testing devices, with best in class customer service and high supply reliability.
- **HollisterStier'** brand loyalty going back 100 years
- Onshore USFDA approved Manufacturing. Dedicated Sales force in the US, serves over 2,000 customers including Allergists, ENT Physicians

Balanced Product Portfolio



Venom Extracts



- Venom extracts includes products for Honey Bee, White-Faced Hornet, Yellow Hornet, Wasp, Yellow Jacket and Mixed Vespid allergies
- Sole supplier in US

Allergenic Extracts



- Allergenic extracts (over 200 products) includes products for Dog, Cat, Mite, Tree Pollen
- Combination of specialized (e.g., Dog) and standardized extracts (e.g., Cat); 2nd largest in the US

Skin Testing Devices



- Multiple skin test system includes ComforTen, Quintest and Quintip
- Differentiated product vs. competition – stainless steel lancets vs. plastic tips ensuring minimal trauma

Moving ahead on three pronged growth strategy





Enlarge US Venom Segment

- Create customer awareness on the Bee sting allergy through targeted marketing campaigns and enlarge the US Venom segment
- Leverage Brand equity in the community



Grow revenues in US Allergenic extracts

- Use Venom products to increase
 customer wallet share in
 Allergenic extracts
- Launch differentiated products e.g. Ultra Filtered Dog product



Penetrate outside US market

- Penetrate the Europe market on the back of strategic partnerships
- Expand the distribution channel in APAC, MEA & LATAM

Sustained growth momentum

			-					
Particulars (Rs. Cr.)	Q3'FY24	Q2'FY25	Q3'FY25	Y-o-Y	9M'FY24	9M'FY25	Y-o-Y	•
Revenue	161	170	171	7%	491	509	4%	•
EBITDA	62	46	48	(23%)	198	157	(21%)	
EBITDA Margin (%)	38%	27%	28%	(1,060) bps	40%	31%	(950) bps	•

- Q3'FY25 revenues grew by 7% on YoY basis.
- Q3'FY25 EBITDA margin decreased YoY due to weakness in exports and production challenges for specific SKU's.
- Production challenges have been solved and normalized production has resumed. We anticipate outside US sales to gradually improve.
- We expect EBITDA margins to revert to normalised levels, starting from Q4'FY25.


٠



3 CDMO - Sterile Injectables Demand expected to outpace the supply by 2027



Global CDMO-SI Market Size (in USD Bn.)



From 2023-27, For vial outsourcing sub-market, Vial filling **Demand > Supply (6.8 Bn. units vs. 6.1 Bn. units)**

The business is engaged in Fill and Finish for Sterile Injectables, where a sterile drug is transferred from a filling needle into a sterile vial and then a stopper is applied, except in cases, where the drug requires sterile lyophilization.

Growth Drivers & Key Trends

- Increase in demand: Increasing number of drugs/injectable in development pipeline driven by biologics (65%+ of current pipeline) and LOEs
- Increase in outsourcing: Outsourcing expected to increase, driven by limited internal capacity and capabilities, cost reduction initiatives and big pharma focus on internalizing specialized capabilities, e.g., Proteins, RNA, Peptides
- **Significant shortages:** Since 2015, 50-60% of new drug shortages in the US have been injectables, signaling need for significant on-shoring
- Demand Supply Gap expected to widen further with increasing consolidation, e.g., Novo Holding acquired Catalent for enterprise value of USD 16.5 Bn. This transaction may further reduce the overall capacity available for outsourcing, given Novo is expected to use capacity for manufacturing their anti-obesity drugs.

Structurally attractive market with key differentiators driving our growth

Strong Entry Barriers

- Majority of commercial contracts are typically long duration (typically 3 years or more with auto renewal)
- Greenfield expansion is considerably difficult due to high up-front capex required with ongoing opex to support initial product commercialization
- Innovator companies prefer onshore North American manufacturers with a good quality track record in light of continuing supply challenges
- Attractive niches & Technology (e.g., Isolator Technology, Multi Dose Preservative Free ophthalmic drops, etc.) have emerged, driven by requirements of differentiated technologies, higher quality standards, people capabilities and capital investment
- **High switching costs for customers** due to significant tech transfer time (18-24 months), other challenges, e.g., quality
- Stringent regulatory requirements (FDA) for sterile manufacturing, with ever evolving landscape making difficult for new entrants


Key Differentiators

- Deep and long-term relationships with our customers
 Top 10 Customers have been with us 5+ years.
- Customer satisfaction is strong with 90%+ repeat
 Customer business rate
- Serving 5 of the top 20 pharma companies globally
- On Shore Manufacturing facilities in Spokane, US and Montreal, Canada
- Co-invested capacity with US govt., advanced isolator technologies are part of our expansion, meeting both regulatory & customer requirements
- Steady quality track record in past audits including inspections from US FDA, ENVISA Brazil and others
- Focused core competency in Sterile Fill & Finish and Ophthalmic (ointments, liquids & creams) sterile products





Collaborative partner with unique capabilities & strong customer relationships



Full Suite of Services with On-shore manufacturing

Strong Quality track record

Strong

Customer

Relationships


- Can handle Vial size from 2ml to 100 ml with batch size up to 2,000 ltr.
- **Full suite of services** including sterile fill and finish (Liquid & Freeze dried), Ophthalmic (Liquids, Ointments and creams) and Biologics
- Strategically located on-shore manufacturing footprint in North America


- Steady quality track record in past audits at each location including inspections from FDA, ENVISA and others
- Stability in core portfolio at Spokane with **multiple products having patent protection** and limited competition

- Serve leading pharmaceutical companies globally
 - Long standing relationship with customers with some longer than10 years and 90%+ repeat business rate
 - Customer-focused approach with strong Tech Transfer & Project Management collaboration from the development phase
 - 25+ Customers across the world



Doubling of capacity with state of the art technology at Spokane on track; Incremental revenue potential of \$160m - \$180m





- Doubling Spokane capacity of sterile fill and finish (both liquid and lyophilization)
- Total investment at USD 285 Mn. Incl. US Govt. funding USD 149.6 Mn.
- Media fills successfully completed on Line 3. Multiple Technology transfers
 underway and commercial revenue in FY26 / FY27

Driving Revenue growth




Particulars (Rs. Cr.)	Q3'FY24	Q2'FY25	Q3'FY25	Y-o-Y	9M'FY24	9M'FY25	Ү-о-Ү
Revenue	303	302	306	1%	858	932	9%
EBITDA	37	89	51	38%	134	197	47%
EBITDA Margin (%)	12%	29%	17%	450 bps	16%	21%	550 bps

- Q3'FY25 revenue stable YoY. Montreal facility restarted operations in Q3'FY25 and operated for partial quarter.
- Q3'FY25 EBITDA margins increased YoY however decreased QoQ due to semi annual shutdown in Q3'FY25


4 CRDMO: Drug Discovery Services, CDMO & API



Both Drug Discovery Services and API/Formulation Development markets are expected to grow at ~5-6% CAGR



API/Formulation Development Market Size (USD Bn.)



Growth Drivers for Drug Discovery Market

- Large Pharma companies to de-risk their supply chain by adding "friend sourcing" locations. Biosecure Act aims to prohibit US Govt. and US life sciences companies, (who are receiving federal grant money) to work with biotechnology service providers that are connected to foreign adversaries.
- Rise in **specialized discovery technologies** such as ADCs and oligonucleotides

Growth Drivers for API / Formulation development Market

- Focus on integrated service offering ranging from discovery to development
- Rapid momentum in specialized CDMO services to support **ever increasing clinical trials,** e.g., High potency APIs with stringent exposure control requirements
- Rising share of biologics along with increasing investments in biologics for new niche modalities

CDMO API market

CDMO API Market is estimated to grow at a CAGR of ~ 6%+



CDMO API Market Size (USD Bn.) cagr: +6% ~ 130 + 18 ~ 95 + 12 12 99 75 2023 2028 HPAPI Large Molecule Small Molecule

Growth Drivers for API Market

- Although API market is dominated by the small molecules, higher growth is experienced by HPAPIs and large molecule segments
- Cost competitiveness is the key including backward integration into major KSMs to mitigate pricing pressures on the finished good formulation companies and ensuring supply continuity
- Rising interest of companies in manufacturing **custom generics** for innovators, ensuring higher margins
- Signals of a positive rebound for the CDMO industry are also driven by the BIOSECURE Act, providing a positive tailwind for Indian Industry

CRDMO : Drug Discovery Services & API

We provide end to end CRDMO services for drug substance in small molecules






Drug Discovery Services

Three Pronged growth strategy







Maximize market penetration & Transform operations by increasing cost effectiveness & asset utilisation



State of the art GMP manufacturing facility spanning over 41 acres with 7 multi stream manufacturing blocks

Facility inspected by FDA, PMDA Japan, KFDA Korea, ANVISA Brazil, TGA Australia

Dominant position in select therapies

- Comprehensive portfolio comprising of APIs from various therapeutic area -Central Nervous System, Cardiovascular System, Anti-infective and Antidiabetic
- Among the largest producers for API's such as, Oxcarbamazepine, Carbamazepine, Pinaverium, Resperidone, Donepezil, Lamotrigine, Meclizine, Azithromycin & Valsartan
- Reach to 50 countries, Servicing 160+ customers

Strategy going forward

- Maximize penetration of APIs : Fortifying sales in USA, Japan, LATAM & MENA
- Transform operations towards CDMO: Leverage GMP manufacturing capabilities for Innovative APIs (CDMO)
- **Custom Manufacturing** : Partner with large pharma to manufacture products requiring life cycle mgmt.
- Increase backward integration: De-risk by increasing backward integration & follow China plus one strategy for sourcing

CRDMO DDS: Increasing revenue share from large pharma clients



CRDMO API: Focus on profitable products ; Taking initiatives to reduce operating costs

Drug Discovery Services

Particulars (Rs. Cr.)	Q3'FY24	Q2'FY25	Q3'FY25	Y-o-Y	9M'FY24	9M'FY25	Y-o-Y
Revenue	114	151	150	32%	332	414	25%
EBITDA	30	36	39	27%	78	96	24%
EBITDA Margin (%)	27%	24%	26%	(90) bps	23%	23%	(20) bps

API

Particulars (Rs. Cr.)	Q3'FY24	Q2'FY25	Q3'FY25	Y-o-Y	9M'FY24	9M'FY25	Y-o-Y
Revenue	138	127	142	3%	480	399	(17%)
EBITDA	11	12	20	82%	39	49	24%
EBITDA Margin (%)	8%	10%	14%	620 bps	8%	12%	400 bps

Drug Discovery Services

- Q3'FY25 revenue increased 32% YoY due to increase in revenue from new contracts from large Pharma customers
- Q3'FY25 EBITDA increased 27% YoY on the back of revenue growth

API

- Q3'FY25 revenue stable YoY. Industry wide pricing pressure continues
- Q3'FY25 EBITDA margins increased YoY due to cost optimization efforts and improvement in product mix


CRDMO Segment

Particulars (Rs. Cr.)	Q3'FY24	Q2'FY25	Q3'FY25	Y-o-Y	9M'FY24	9M'FY25	Y-o-Y
Revenue	252	278	292	16%	812	813	0%
EBITDA	41	48	59	42%	117	145	24%
EBITDA Margin (%)	16%	17%	20%	370 bps	14%	18%	340 bps









■ Developed Markets ■ Pharmerging Markets ■ RoW Markets

Overall Market

 Overall market is growing on the back of increase in Chronic disease prevalence, loss of exclusivity for innovator products negated by pricing pressure in select markets

Developed Market

- US market is expected to grow ~2% with early signs of decrease in price reductions.
- Non-US market is expected to grow by ~5 to 7% with margins & regulatory approval timelines varying by market. Key differentiators are cost competitiveness and supply reliability.

India Market

 India market is expected to grow in excess of 10%. Key differentiators are brand building and In-clinic effectiveness of sales team

Generics

Continued profitable operations in 9M'FY25





Key Products & Facilities

- Therapeutic areas Cardiovascular System, Central
 Nervous System, Gastrointestinal and Multi Specialty
- Global presence with serving more than 50 countries including US, Europe, Canada, Japan, Australia and RoW
- Building branded generics business in India in the field of Cardiovascular diabetes & Multi Specialty
- Derisking product supplies through building a robust CMO network
- USFDA classifies Roorkee Facility as "Voluntary Action Indicated (VAI)" in April'24.

Generics



Engineered turnaround by improving quality, optimizing cost & scaling Non US international business



Continuous Quality Improvement

Implemented a large scale **quality improvement** program in Roorkee facility.



Continuous Cost Optimisation

Implemented cost optimization initiatives of **Rs. 150 Cr. in FY24.**

Outsourcing of manufacturing to CMO network in US



Scaled up Non US International business

Scaled Non US international business and achieved highest ever sales in FY24

Generics Growth Strategy for key markets





Grow the profitable Non-US International market

- Focus on scaling 2 key markets to triple digit revenue in INR Cr. (B2B2C)
- Offer a portfolio of products to 50+ markets (B2B)
- Launch new products through In-Licensing



Build business in Indian Market

- Build and Scale branded generics business in India
- Develop 3 to 4 profitable therapeutic area divisions.
 Demonstrated successful blueprint by achieving profitability in CVD division in Q4'FY24 and H1'FY25



Focus on profitability in the US Market

- Focus on profitable sustainable portfolio
- Relaunch products & grow exports through Roorkee Facility
- Get approval of ANDAs (33) in the pipeline and launch new products.

Generics

Continued profitable operations in 9M'FY25

Particulars (Rs. Cr.)	Q3'FY24	Q2'FY25	Q3'FY25	Y-o-Y	9M'FY24	9M'FY25	Y-o-Y
Revenue	199	173	200	0%	573	528	(8%)
EBITDA	(31)	21	30	198%	(102)	40	139%
EBITDA Margin (%)	(15%)	12%	15%	3,060 bps	(18%)	8%	2,540 bps

- Q3'FY25 revenue stable YoY
- Q3'FY25 EBITDA sharply improved YoY due to overhead cost savings & profitable product mix.



6 Proprietary Novel Drugs *Clinical stage precision therapeutics*



Advancing potent molecules to address unmet medical needs in Oncology & Auto immune diseases

Program	Mechanism	Indications	Lead Optimization	Pre - Clinical (IND)	Phase I /II	Milestones
JBI-802	coREST Inhibitor/ Epigenetic Modulating Agent	ET (Essential thrombocythemia)/MPN (Myeloproliferative neoplasms), NSCLC (Non- small cell lung cancer)			0	Phase I data suggests therapeutic potential. First Patient dosing done. Interim Phase II data in 2025
JBI-778	PRMT5 Inhibitor Brain Penetrant	EGFR (Epidermal Growth Factor receptor) refractory NSCLC, ACC (Adenoid cystic carcinoma), High Grade Glioma			0	Phase I trial under progress First Patient dosing done Interim Phase I data in 2025
JBI-2174	PD-L1 Inhibitor Brain Penetrant	Brain tumor and metastases		0		IND enabling
JBI-1044	PAD4 Inhibitor	Oncology and auto-immune disease		0		IND enabling
Other	Various	Various	0			Undisclosed Research Programs

Two Clinical stage drugs under development with significant value inflection potential on clinical outcome


Key Indications for JBI - 802



Disease Indications	Rationale	JBI - 802 Response
Non-Small cell lung cancer (NSCLC) Investigator-initiated study	 STK11 mutation is observed in10-15% NSCLC (85 % of lung cancer is NSCLC). Patients with STK11 mutations have a lower survival rate and are resistant to immune checkpoint therapy (like Keytruda, Atezolizumab, etc.) 	One patient with NSCLC having STK11 mutations showed significant response on JBI-802, while not responding to previously administered doublet Immune checkpoint therapy. Preclinical animal model study have shown synergistic effects of JBI-802 with immune checkpoint inhibitors
Essential Thrombocythemia (ET) Company sponsored study	 ET is a rare blood cancer that causes the bone marrow to produce too many platelets which can lead to an increased risk of developing blood clots resulting in stroke and heart attack Limited options for patients who are refractory to the first line of therapy 	JBI-802 has shown to reduce platelet in human clinical trial which is mediated by LSD1 inhibitor. JBI-802 has better safety profile compared to the competitor (no Dysgeusia and anemia)
Post MPN-AML (Myeloproliferative neoplasms- Acute myeloid leukemia) Investigator-initiated study	 MPNs are a group of blood cancers that cause increased production of blood cells, mainly affecting red blood cells, platelets, or white blood cells. Progression from MPN to AML (Acute Myeloid Leukemia) is a serious complication, occurring in about 5-10% of MPN patients. No effective therapy available (Survival in adults is only 5 months) 	JBI-802 shows superior efficacy in preclinical in-vivo efficacy studies compared to LSD1 only and HDAC6 only inhibitors

Phase Two & Investigator led clinical trials status for JBI-802





Trial Status

Company Sponsored Phase 2 trial ; First patient dosing done ; Interim data by 2025

- ET is a rare blood cancer that causes the bone marrow to produce too many platelets leading to stroke and heart attack. JBI-802 has shown to reduce platelet in human clinical trial which is mediated by LSD1 inhibitor.
- Potential better safety and efficacy than Bomedemstat (Merck Phase 3), which Merck acquired for USD 1.35 billion

Investigator led trial under planning

- MPN are blood cancers that cause increase production of blood cells. Progression from MPN to AML is serious complication occurring in MPN patients
- High unmet need for effective therapy with survival only for 5 months

Investigator led trial under planning

- Demonstrated clinical efficacy in JBI-802 in one patient in phase 1 study
- Patients with STK11 mutations have a lower survival rate and are resistant to immune check point therapy

Key Indications for JBI - 778;



Disease Indications	Rationale	JBI – 778 Response
Non-Small cell lung cancer (NSCLC) with or without brain metastases	 EGFR (epidermal growth factor receptor) mutations are observed in 10 - 50% of non-small cell lung cancer patients EGFR mutations is almost double in patients with NSCLC with CNS metastases compared with patients without CNS metastases Recently PRMT5 inhibitors have been shown to be effective in NSCLC patients who is resistant to Osimertinib (3rd Generation EGFR inhibitors) A brain penetrant and substrate-specific PRMT5 inhibitor offers potential therapeutic opportunity 	 PRMT5 mechanism is relevant to EGFR inhibitor refractory cell lines both in <i>vitro and in vivo</i> JBI-778 is potent PRMT5 inhibitor having good plasma and brain exposure and has a potential to treat patients who are non- responders to the EGFR inhibitors with or without brain metastases
High Grade Glioma	 High-grade gliomas account for approximately 15 to 20 % of CNS tumours in children and adolescents Isocitrate dehydrogenase (IDH) mutant gliomas are the most common malignant primary brain tumors diagnosed in patients younger than 50, an important cause of morbidity and mortality Previous PRMT5 inhibitors shown CR in IDH+ patients but faced tox issues impeding further development 	 JBI-778 has superior brain exposure and substrate competitive binding has established superior safety in preclinical setting JBI-778 has shown excellent results in pre-clinical in vivo model of glioma

Continue to invest in a calibrated manner



Particulars (Rs. Cr.)	Q3'FY24	Q2'FY25	Q3'FY25	Y-o-Y	9M'FY24	9M'FY25	Ү-о-Ү
Revenue	0	0	0		0	0	
EBITDA	(5)	(3)	(5)	(13%)	(23)	(14)	37%

Continue to invest in a calibrated manner in two lead programs

٠

JUBILANT PHARMOVA

Consolidated Reported Financials – Q3'FY25 & 9M'FY25

Total Income growth (YoY) along with EBITDA margin expansion & PAT growth (YoY)

Particulars (Rs. Cr.)	Q3'FY24	Q2'FY25	Q3'FY25	Y-o-Y	9M'
			i		
Revenue	1,677	1,752	1,822	9%	4,9
Other Income	36	22	9		5
Total Income	1,713	1,774	1,831	7%	4,9
EBITDA	267	311	296	11%	7
EBITDA Margin (%)	15.6%	17.5%	16.2%	60 bps	14
Exceptional Income / (expense)	0	(14)	(19)		
PBT	101	144	131	29%	2
PBT Margin	5.9%	8.1%	7.1%		4.
Normalised PBT ¹	101	159	149	48%	2
Normalised PBT Margin	5.9%	8.9%	8.2%	230 bps	4.
		-			
Reported PAT	66	103	101	52%	1
Reported PAT Margin	3.9%	5.8%	5.5%	160 bps	2.
Normalised PAT ¹	66	103	104	57%	1
Normalised PAT Margin	3.9%	5.8%	5.7%	180 bps	2.

9M'FY24	9M'FY25	Y-o-Y
4,944	5,306	7%
54	45	
4,999	5,351	7%
704	873	24%
14.1%	16.3%	220 bps
0	363	
224	775	245%
4.5%	14.5%	
224	412	84%
4.5%	7.7%	320 bps
135	685	409%
2.7%	12.8%	1,010 bps
135	277	106%
2.7%	5.2%	250 bps

- Q3'FY25 **Revenue grew by 9% YoY** on the back of growth in revenue across all segments
- Q3'FY25 **EBITDA increased 11% YoY** due to improved performance in CDMO Sterile Injectables, CRDMO and turnaround in Generics business.
- Q3'FY25 Exceptional items mainly includes expenses pursuant to temporary suspension of manufacturing operations for remediation of OAI at CMO Montreal

Q3'FY25 **Normalised PAT increased 57% YoY** due to improved operating performance and reduction in finance cost

Key Ratios *Net Debt / Ebitda continues to improve*



Particulars (Rs. Cr.)	Mar 31, 2024	Dec 31, 2024
Net Debt (On constant currency, Net of DIC)	2,457	1,654
Net Debt / Equity	0.46	0.29
Net Debt / EBITDA (TTM)	2.5	1.4

Net Debt / Ebitda continues to improve

٠


٠

USD 125 million voluntary prepayment in YTD FY25, including USD 25 million in Jan'25

Sustainability



Received KPMG ESG Excellence award for Mid / Small Cap category in the Pharma & Healthcare sector in FY25



Summary – Q3'FY25 Radio Pharmaceuticals : New products and Ruby-Fill® maintaining growth momentum Radio Pharmacies : Industry wide Technetium shortage impacted business, Commercial distribution of PLYARIFY® started Allergy Immunotherapy : Q3'FY25 revenue grew YoY; EBITDA margins have started to improve **CDMO Sterile Injectable : Capacity expansion** at Spokane on track. Media Fills successfully completed on Line 3 3 CRDMO DDS: Continue to increase revenue share from large pharma clients. Medium term outlook continues to be positive **CRDMO API :** Focus on profitable products. Taking initiatives to reduce operating costs

Generics : Continued profitable operations in 9M'FY25



Prop Novel Drugs : **First patient dosed** in both lead programs

Financial Results Table



Total Income (Rs. Cr.)	Q3'FY24		Q2'FY25		Q3'FY25		9M'FY24		9M'FY25		FY24	
Revenue (A)	1,677		1,752		1,822		4,944		5,306		6,703	t
a. Radiopharma	752		820		841		2,184		2,493		3,001	t
Radiopharmaceuticals	241		251		265		696		778		952	Ī
Radiopharmacies	511		568		576		1,488		1,715		2,050	T
b. Allergy Immunotherapy	161		170		171		491		509		679	
c. CDMO Sterile Injectables	303		302		306		858		932		1,117	
d. CRDMO	252		278		292		812		813		1,093	
Drug Discovery Services	114		151		150		332		414		449	
CDMO – API	138		127		142		480		399		645	
e. Generics	199		173		200		573		528		775	I
f. Proprietary Novel Drugs	0		0		0		0		0		0	Ι
Unallocable Corporate Income	11		10		11		27		30		38	
Other Income (B)	36		22		9		54		45		69	
Total Income (A+B)	1,713		1,774		1,831		4,999		5,351		6,772	
EBITDA (Rs. Cr.)	Q3'FY24	Margin	Q2'FY25	Margin	Q3'FY25	Margin	9M'FY24	Margin	9M'FY25	Margin	FY24	T
a. Radiopharma	175	23%	126	15%	129	15%	415	19%	394	16%	584	
Radiopharmaceuticals	126	52%	120	48%	125	47%	352	51%	370	48%	477	I
Radiopharmacies	10	2%	6	1%	5	1%	18	1%	24	1%	56	T
b. Allergy Immunotherapy	62	38%	46	27%	48	28%	198	40%	157	31%	273	
c. CDMO Sterile Injectables	37	12%	89	29%	51	17%	134	16%	197	21%	192	Ι
d. CRDMO	41	16%	48	17%	59	20%	117	14%	145	18%	169	
Drug Discovery Services	30	27%	36	24%	39	26%	78	23%	96	23%	106	
CDMO – API	11	8%	12	10%	20	14%	39	8%	49	12%	63	
e. Generics	(31)	(15%)	21	12%	30	15%	(102)	(18%)	40	8%	(141)	I
f. Proprietary Novel Drugs	(5)		(3)		(5)		(23)		(14)		(30)	Ι
Unallocable Corporate (Expenses) / Income	(13)		(16)		(16)		(35)		(46)		(55)	I
Total EBITDA	267	15.6%	311	17.5%	296	16.2%	704	14.1%	873	16.3%	994	Γ

Annexure

Executive Leadership Team





Shyam S Bhartia Chairman



Hari S Bhartia Co-Chairman



Priyavrat Bhartia Managing Director



Arjun S Bhartia Joint Managing Director



Arvind Chokhany Group CFO, Whole-time Director



Shantanu Jha Group CHRO



Dr. Tushar Gupta COO, CRDMO Head, Corporate Strategy

Executive Leadership Team





Harsher Singh CEO - Jubilant Radiopharma



Giuliano Perfetti CEO - CRDMO, Biosys



Kyle Ferguson CEO – Allergy Business



Dr. Jaidev Rajpal CEO - Jubilant Generics



CEO - CDMO




Dr. Syed Kazmi CEO - Jubilant Therapeutics



JPM Business Strategy


To strengthen the unique position of each of the business unit to enhance shareholder value



Shareholding Pattern



As on 31st Dec 2024



GLOSSARY



Abbreviation	Details	Abbreviation	Details
CVS	Cardiovascular System	MEA	Middle East Africa
CNS	Central Nervous System	LATAM	Latin America
CDMO	Contract Development Manufacturing Organization	LOE	Loss of exclusivity
CRDMO	Contract Research & Development Manufacturing Organization	FDA (US)	U.S. Food and Drug Administration
F18	Fluorine-18 Radioisotope	PMDA (Japan)	Pharmaceutical and Medical Device Agency
PSMA	Prostate Specific Membrane Antigen	KFDA (Korea)	Korea Food Development Authority
Lu177	Lutetium-177 Radioisotope	. ,	Brazilian Health Regulatory Agency
Ac225	Actinium-225 Radioisotope		
MAA	Macro Aggregated Albumin		Therapeutic Goods Administration
DTPA	Diethylenetriaminepentacetic Acid-Chelating Agent	API	Active Pharmaceutical Ingredient
HICON	Pharmaceutical Grade Radioactive Iodine	MENA	Middle East North Africa
I 131	lodine-131 Radioisotope	GMP	Good Manufacturing Practices
MIBG	Metaiodobenzylguanidine	B2B2C	Business-to-Business-to-Consumer
USP (USP 825	U.S. Pharmacopeia (USP) general chapter ,825 (Related to Radiopharmaceuticals: Preparation,	B2B	Business-to-Business
Guideline)	Compounding, Dispensing, and Repackaging)	ET/MPN	Essential thrombocythemia / Myeloproliferative neoplasm (rare chronic blood cancer)
Ga 68	Gallium-68 Radioisotope	COREST	CRISPR-Cas9 Endomorphic RNA Symptomatic Inhibitor (RNA based therapy targeting genetic
Rb	Rubidium (chemical element)	Inhibitor/	disease)
Sr	Strontium (chemical element)	Epigenetic Modulating	Medications that modify gene expression patterns
Cu 64	Copper-64 Radioisotope	Agent	
NRC	Nuclear Regulatory Commission (U.S.)	PRMT5	Protein Arginine Methyltransferase 5 inhibtor (Blocks enzyme activity involved in adding methyl
GPOs	Group Purchasing Organisation	Inhibitor Brain	groups to arginine residues, affecting gene expression regulation)
IDNs	Integrated Delivery Network	Penetrant	Cerebral blood flow enhancers or cognitive-enhancing drugs (supplements)
SCIL	Sublingual immunotherapy (Allergy treatment - Dust mites & Seasonal allergy)	PD-L1 Inhibitor	Programmed death Ligand-1 inhibitor (blocks the PD-L1 pathway, enhancing immune response
SCIT	Subcutaneous Immunotherapy (Allergy treatment Insect venom, pet dander, Mold, and other allergens)	PAD4 Inhibitor	against cancer cells) poly(ADP-ribose) polymerase 4 inhibitor (Disrupts DNA repair mechanisms in cancer cells, leading to their death)
APAC	Asia Pacific	LSD1/HDAC6	Lysine specific demethylase 1/Histone deacetylase 6 inhibtor (Blocks enzymes involved in
MEA	Middle East Africa	inhibitor	modifying histones, impacting gene expression regulation in cancer therapy)
NSCLC	Non-small cell lung cancer	NSCLC	Non-small cell lung cancer
SCLC	Small cell lung cancer	SCLC	Small cell lung cancer

For More Information



For Investors: Pankaj Dhawan Jubilant Pharmova Limited Ph: +91 120 436 1105 E-mail: Pankaj.dhawan@jubl.com

For Media: Sandipan Ghatak Phone: +91-120 436 1026 E-mail: sandipan.ghatak@jubl.com

Siddharth Rangnekar

CDR India Ph: +91 +91 9769919966 E-mail: siddharth@cdr-india.com

Ryan Marshall Madison Public Relations E-mail: ryan.marshall@madisonpr.in Phone number: +91 9810047944